Drug
Nebulized Albuterol
Nebulized Albuterol: highest development phase Post-Market, developed by Sumitomo Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Sumitomo Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| nebulized albuterol (2.5 mg/3ml/dose) NCT00325767 | Post-Market | Mucociliary Clearance |
Latest
No recent events.
Follow Nebulized Albuterol on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.